Trinov Works Better in Women

I have discussed Trinov (formerly known as the Brotzu Lotion) a number of times on this blog. My main reason for doing so is because it is the first at least somewhat reputable new hair loss product that has been approved in many years.

Trinov is a non-prescription lotion that is is manufactured by well known Italian pharmaceutical company Fidia Farmaceutici. Trinov is currently sold by a number of Italian companies, and will be available for sale in the US in 2019.

Is Trinov going to bring back your childhood hairline? Not even close. Will it even bring back hair that you have lost more than several years ago? I highly doubt it, even if initial reports from a few years ago suggested that it could bring back hair that was lost up to five years ago.

However, I do believe in the science behind it, as I have stated a number of times before. I would not be surprised if Trinov ended up being at least as effective as Minoxidil.

Trinov
Trinov

Trinov consists of a three-pronged attack on hair loss via topical liposomal delivery of:

  1. Dihomo-γ-linolenic acid (DGLA), which improves microcirculation and blood and nutrient flow to the follicles.
  2. S-equol, which inhibits 5α-reductase enzyme activity. This reduces the conversion of testosterone into dihydrotestosterone (DHT).
  3. Propionyl-L-carnitine, which promotes lipid metabolism and stimulates energy production.

S-equol will obviously not inhibit DHT to the same extent as Dutasteride or Finasteride.

Trinov Works Better in Women than in Men

Dr. Giovanni Brotzu and various co-authors recently published a new study on Trinov. I am surprised that no-one on here or on the hair loss forums mentioned it, but there were some concrete findings in there. The most interesting ones:

  • Daily topical applications of the lotions resulted in a hair count that significantly increased for women and marginally increased for men after 6 months of treatment.
  • Significant increase in anagen hair and a significant decrease in telogen hair were observed starting from 3 months in male and 1 month in female patients.

So, in a rarity, women may benefit more from a hair loss treatment than men. As a male, I will still gladly take a cessation in hair loss and a marginal increase in new hair count if the above findings are really true.

It seems like there were two lotions in the study.

The male lotion was: TRINOV Lozione Anticaduta Uomo.

The female lotion was: TRINOV Lozione Anticaduta Donna.

Trinov E-Book

Several days ago commentator “Hope” posted a link to the new official Trinov website. You can read the Trinov e-book on there. Some highlights after translation:

The patented formula consists of phospholipid liposomes, i.e., microscopic vesicles formed by a double phospholipid state that protects the ingredients and allows controlled, local and gradual release, improving absorption in the application site.

After six months of daily application of TRINOV men’s anti-fall lotion the increase of total number of hair is observed in 63% of subjects treated; more than 70% perceive a minor fall, improve the condition of the scalp and report feeling healthier and stronger hair.

After 6 months of daily application of TRINOV Women Fallout Lotion the increase in the number total hair is observed in 90% of subjects treated; more than 70% report an improvement in the state of the scalp and refers to feel healthier and stronger hair, and almost 70% perceives one lower fall.

— Per part of the translation, it seems like Dr. Brotzu’s son Giovanni Brotzu is the CEO of the American company Liposome Advanced research LLC. Could not find much on the company in my few minutes of research.

— The first two new Trinov Youtube channel videos were not very encouraging.

Update: Fidia press release.

— Also see Trinov’s Facebook page.

My Thoughts on Trinov

Trinov will either be:

  • A new product that is similar to or slightly superior to Minoxidil. This would be miraculous, as only two products have ever been approved to treat hair loss (Minoxidil and Finasteride),

Or:

  • Yet another overblown overhyped hair loss product in a long list of them over the past few decades. This time, with the added insult (to us) and ignominy of being approved by a pharmaceutical company;  and of having famous doctors and universities involved in its research and development.

Brief Aclaris ATI-502 Topical Update

Yesterday, Aclaris Therapeutics provided an update regarding its  ATI-502 JAK inhibitor product for the topical treatment of androgenetic alopecia (AGA). It seems like this product was called ATI-50002 in the past? In any event, the main quote:

“AGA-201 Topical – Completed enrollment of this ongoing Phase 2 open-label clinical trial of ATI-502 for the topical treatment of androgenetic alopecia (AGA), also known as male/female pattern hair loss. This trial will evaluate the safety and efficacy of ATI-502 on the regrowth of hair in 31 patients with AGA, and data are expected in the first half of 2019”.

Based on the hype several years ago, I would have thought that Aclaris would be finishing Phase 2 trials by year-end 2018. Will nevertheless take this news in stride.

Big year in 2019 to weed out the players from the fakers.